Researchers have expressed concern over the efficacy of common kidney disease (CKD) drugs, as they are likely to cause unexpected harm to blood vessels.
Researchers have expressed concern over the efficacy of common kidney disease (CKD) drugs, as they are likely to cause unexpected harm to blood vessels. The study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN) indicate that additional studies on the drugs, called phosphate binders, are needed.
Higher blood levels of phosphorus that are still within the normal range have been linked with heart problems, kidney disease, and premature death. Because the kidneys get rid of excess phosphorus by excreting it through the urine, patients with CKD often have elevated blood phosphorus levels.
Drugs called phosphate binders can lower blood phosphorus levels, and while they are approved only for patients with kidney failure, they are often prescribed off-label to patients with CKD. Geoffrey Block, MD (Denver Nephrology) and his colleagues evaluated the effects of these drugs (calcium acetate, lanthanum carbonate, sevelamer carbonate) in patients with moderate to advanced CKD and normal or near normal blood phosphorus levels.
The study included 148 patients who were randomized to receive one of the three phosphate binders or a placebo. The investigators examined patients after three, six, and nine months of treatment. The study is the longest placebo-controlled trial of phosphate binders in patients with CKD conducted to date.
Treatment with phosphate binders significantly lowered patients' urinary phosphorus levels, moderately lowered their blood phosphorus levels, and slowed progression of a parathyroid disorder that is a common complication of CKD, while treatment with placebo did not. Despite these positive effects, phosphate binders did not have any effect on the blood levels of a hormone that regulates phosphate excretion in the urine, and the drugs caused calcium build-up in blood vessels, which can lead to heart problems. Heart disease is the leading cause of death in patients with CKD.
These findings call into question the safety and effectiveness of phosphate binders in patients with CKD.
Advertisement
Source-Newswise